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To characterize newly arising replication of human immunodeficiency virus (HIV) type 1 in vivo at the cellular
level, distinct viral RNA species in peripheral blood mononuclear cells (PBMCs) from HIV-1–infected patients
were monitored during 2 weeks of structured treatment interruption (STI). HIV-1 RNA encoding tat/rev and
PBMC-associated virions were almost completely depleted during antiretroviral therapy and emerged simul-
taneously after 2 weeks of STI, thus specifically reflecting productive viral infection at the cellular level. The
magnitude of these correlates of reappearing cellular viral replication was predicted by during-therapy levels
of nef transcripts in PBMCs. Significant rebound of plasma viremia, representing the progeny of a broader
range of anatomical compartments, preceded and predicted productive infection in PBMCs. Thus, cellular
viral rebound in PBMCs likely was primed before STI by the expression of nef in HIV-1–infected PBMCs that
lacked virion production and was subsequently triggered by the plasma viremia that preceded the recurrence
of productively infected PBMCs.
Despite their power to suppress HIV-1 replication [1]
with subsequent clinical benefit [2–4], current antiret-
roviral treatment strategies cannot eradicate the virus
[5–8]. Both residual HIV-1 replication and viral latency
contribute to the persistence of the infection in the face
of potent therapy [9, 10]. Evidence of ongoing, low-
level HIV-1 replication in a fraction of patients receiving
successful potent antiretroviral therapy has been shown
by viral sequence evolution, despite virtual suppression
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of plasma viremia [11–13], by the fact that both stable
and decaying residual plasma viremia can be observed
during potent antiretroviral therapy [14], and by the
observation that the subpopulations of lymphocytes in-
fected with different HIV-1 quasi species show different
rates of decay and replenishment in patients receiving
potent antiretroviral therapy [10]. However, residual
active replication may occur in only a fraction of suc-
cessfully treated patients [11–13], and its effect on per-
sistence of HIV-1 during therapy may be low [10, 15].
Similarly, persistence of productively infected cells is
rare under conditions of potent antiretroviral therapy
[16–19].
In contrast, the pool of latently HIV-1–infected cells
is a major viral reservoir during therapy [5–7, 18, 20–
23]. Hence, HIV-1 DNA persisting in virtually all HIV-
1–infected patients, regardless of their treatment, has
predominantly been related to nonproductively in-
fected cells [18, 22, 24].
To facilitate differentiation of residual active HIV-1
replication and persistence of latently infected cells, po-
tential markers indicating ongoing HIV-1 replication
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and/or productively infected cells have been examined. 2LTR
viral DNA episomes (by-products of retroviral cDNA synthesis)
were reported to be short-lived and have been proposed as
markers for recently infected cells [25]. However, 2LTR epi-
somes are stable in vivo and in cultured HIV-1–infected cells
in vitro [26–29] and thus do not specifically indicate new
rounds of infection [26, 30]. Conversely, cell-associated HIV-
1 RNA [16, 18, 31–34] may be a more-specific surrogate marker
of ongoing replication.
Therefore, in the present study, we examined a panel of
different HIV-1 RNA species. In addition to plasma levels of
HIV-1 RNA, we analyzed expression of 4 cell-associated viral
RNA species: intracellular and extracellular unspliced RNA
(usRNA), multiply spliced RNA (msRNA) encoding tat/rev, and
msRNA encoding nef.
Intracellular usRNA, when residing in the nucleus, is the
primary viral transcript from which all other viral RNA species
are derived by splicing. After its translocation into the cyto-
plasm, usRNA serves as mRNA for the Gag and Pol proteins
and, when it is located near the cell membrane, is encapsidated
into virions [35].
Cell-bound viral RNA encapsidated in virions (extracellular
usRNA) has been shown to be significantly associated with
productively infected cells in peripheral blood [16] and lym-
phoid tissue [18]. Similarly, a particular class of msRNA en-
coding the Tat and Rev proteins has been related to productively
infected cells [16, 18, 31, 32, 34, 36]. Since tat mediates high-
level viral transcription of the proviral DNA [37, 38] and rev
is responsible for efficient translocation of a majority of viral
mRNA species into the cytoplasm (where they can be trans-
lated) [39], expression of msRNA encoding tat/rev may be
viewed as a surrogate for the efficient expression of viral pro-
teins. Nevertheless, each of the latter 2 parameters, msRNA
encoding tat/rev and extracellular usRNA, is not an unambig-
uous sign of productively infected cells per se, since msRNA
encoding tat/rev can be observed in cultured latently infected
cells [40] and extracellular usRNA may, in part, also represent
virions captured by uninfected cells in trans [16, 18].
A second class of msRNA species that encode the Nef protein
may, like intracellular usRNA, play a role in all stages of the
intracellular viral life cycle. Although nef is not strictly required
for viral replication [41], it affects early stages of infection [42–
44], the productive phase of infection [45, 46], and the tran-
sition from latency to virus production [44, 47] through its
pleiotropic effects on the intra- and extracellular environment
and on the HIV-1 virion. These distinct viral RNA species were
monitored longitudinally during structured treatment inter-
ruption (STI), to characterize their appearance during the tran-
sition from latent or persistent to productive infection.
We found that the expression of msRNA encoding tat/rev
occurred concomitant with the reemergence of peripheral
blood mononuclear cell (PBMC)–associated HIV-1 particles.
Thus, parallel increases in these 2 types of viral RNA species
reflected reappearance of productively infected cells. Further-
more, we demonstrate that, in peripheral blood, rebound of
such virus-producing cells after STI is predicted by during-
therapy levels of residual nef-encoding transcripts and by the
levels of plasma viremia that preceded cellular viral rebound.
PATIENTS, MATERIALS, AND METHODS
Patients and specimens. Patients were enrolled in the Swiss
Spanish Intermittent Therapy Trial (SSITT). Patients provided
written, informed consent, in accordance with the guidelines
of the Ethics Committee of the University Hospital Zu¨rich. A
prospective virological substudy was performed for 28 of the
29 patients enrolled in SSITT at the Zu¨rich center. One patient
was excluded because polymerase chain reaction (PCR) assays
could not be performed properly, most likely because the pa-
tient was infected with HIV-1 subtype A. At baseline (during
therapy), plasma viremia of patients was !50 HIV-1 RNA cop-
ies/mL (median, 11 HIV-1 RNA copies/mL) for a median of
25 months; the median CD4+ T cell count was 717 cells/mL
(table 1). Virological and immunological outcomes of the pres-
ent study have been reported elsewhere [48–54]. The present
article addresses the first 14 days of the study, which included
baseline (when patients were receiving successful therapy) and
2 weeks of STI. Blood samples were obtained from all 28 pa-
tients on days 0 and 14. For a subset of 14 patients participating
in an extended study protocol with frequent blood and PBMC
sampling [26, 51, 53], additional blood samples obtained on
days 4 and 8 were analyzed. PBMCs and plasma were separated
from anticoagulated blood by use of Ficoll-gradient purification
(Lymphoprep; Nycomed) and were frozen at 80C.
RNA extraction. RNA was extracted by use of the RNeasy
mini kit (QIAGEN) [16], and concentrations of extracted total
RNA were measured by use of ribogreen fluorescent dye [55].
Nuclease-digested extracts prepared to obtain extracellular
usRNA and matched preparations of total cell-associated RNA
[16] were monitored for residual cellular RNA by use of real-
time reverse-transcriptase (RT)–PCR for glyceraldehyde phos-
phodehydrogenate mRNA [56].
Quantitation of HIV-1 RNA. Figure 1 depicts the am-
plification strategies used for quantification of the different
classes of HIV-1 RNA. Plasma HIV-1 RNA was quantified by
a modification of the Roche Amplicor Monitor test (version
1.5) [26, 51]. The levels of plasma viremia for the analyzed
patients have been described elsewhere [26, 51] but are in-
cluded here for better clarity. Cell-associated usRNA was dis-
sected into intra- and extracellular fractions [16, 18] and was
RNA Correlates of HIV-1 Replication • JID 2004:190 (1 December) • 1981
Table 1. Baseline characteristics of patients before structured treatment interruption (STI).
Patient
Antiretroviral
therapy received
before STI
Plasma HIV-1
RNA level,
copies/mL
Duration of
virological
suppressiona
before STI,
months
CD4+
T cell count,
cells/mL
101 ddI/d4T/NFV !8 17 719
102 AZT/3TC/IDV !22 32 723
103 ddI/d4T/NFV 25 12 272
104 AZT/3TC/NFV 25 26 515
105 AZT/3TC/IDV !12 26 1269
106 AZT/3TC !3 36 878
107 AZT/3TC/NFV !3 25 544
109 AZT/3TC/RTV !10 31 1115
110 ddI/d4T/NFV 21 12 508
111 ddI/d4T/NFV 14 11 422
112 AZT/3TC/IDV 44 25 347
113 AZT/3TC/RTV 11 20 995
114 AZT/3TC/RTV !6 29 907
115 d4T/3TC/NFV !4 21 570
116 AZT/3TC/IDV !9 32 350
117 AZT/3TC/RTV !3 36 489
118 AZT/3TC/IDV !6 30 832
119 d4T/3TC/SQV/RTV 18 12 440
120 AZT/3TC/IDV !22 28 766
121 d4T/3TC/NFV 16 12 591
122 AZT/3TC/IDV 14 30 669
123 AZT/3TC/RTV !7 25 1335
124 ddI/d4T/NFV 26 19 715
125 ddI/d4T/NFV 42 23 777
126 AZT/3TC/RTV 5 34 842
127 d4T/3TC/NFV !9 22 839
128 AZT/ddI/NFV !7 25 749
129 AZT/3TC/IDV 47 29 398
Median (minimum, maximum) … 11 (3, 47) 25 (11, 36) 717 (272, 1337)
NOTE. AZT, zidovudine; ddI, didanosine; d4T, stavudine; IDV, indinavir; NFV, nelfinavir; RTV, ritonavir; SQV, saquinavir;
3TC, lamivudine.
a Virological suppression is defined as a viral load !50 copies/mL.
quantified by use of a modification of the HIV-1 Monitor test
(Roche) (figure 1B).
msRNA was quantified by duplicate real-time PCR mea-
surements by use of the following primers: ks1 (5′-CTTAGGC-
ATCTCCTATGGCAGGAA-3′) [58], mf83 (5′-GGATCTGTCT-
CTGTCTCTCTCTCCACC-3′), and mf84 (5′-ACAGTCAGAC-
TCATCAAGTTTCTCTATCAAAGCA-3′). For detection, the
following dual-labeled fluorescent probes were used with a fluo-
rescein (FAM) moiety at their 5′ ends and a TAMRA moiety
at their 3′ ends: ks2-tq (FAM5′-TTCCTTCGGGCCTGTCGGG-
TCCC-3′TAMRA) [58] and mf82-tq (FAM5′-TCTTCGTCGC-
TGTCTCCGCTTCTT-3′TAMRA). PCR was performed by use
of a single-tube system (QIAGEN 1-step RT-PCR; QIAGEN)
and an additional “hot-start” using Ampliwax (Applied Bio-
systems), to separate cDNA synthesis and PCR [56], as follows:
aliquots of a lower-phase mix were prepared containing 10 mL
of 1 reaction buffer (including 2.5 mmol/L MgCl2), 4.7 mmol/
L amplification primers (msRNA encoding tat/rev:ks1 and mf83,
total msRNA:mf84 and mf83), fluorescent probes (msRNA en-
coding tat/rev:mf82tq [0.94 mmol/L] and mf2tq [1.88 mmol/L]
and total msRNA:ks2-tq [1.88 mmol/L]), 2.35 mmol/L MgCl2,
and 47 ng/mL poly-A cRNA. Ampliwax was added to each re-
action, and lower phases were sealed by incubation for 5 min at
90C and cooling to room temperature. Upper-phase mix (30
mL of 1.23 reaction buffer [including 3 mmol/L MgCl2]), 0.25
mmol/L primer mf83, 0.63 mmol/L dNTP, 6.3% (vol/vol) enzyme
mix, and 7 mL of template RNA were added. cDNA synthesis
and subsequent amplification were performed in a real-time ther-
mocycler (i-cycler; Biorad) as follows: 30 min at 50C, 15 min
at 95C, and 60 cycles of 10 s at 95C and 1 min at 60C, with
monitoring of fluorescence at 60C. An external standard was
prepared by 10-fold serial dilutions of synthetic msRNA en-
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coding tat/rev, which could be amplified both in the RT-PCR
for total msRNA species and in the assay for RNA species
encoding tat/rev [16]. Calibration was performed by use of the
i-cycler software (Biorad). Both assays for msRNA were equally
sensitive (1–5 copies/PCR), as shown by measurement of di-
luted synthetic msRNA.
Genotypic analysis of patients. PBMC DNA from partic-
ipants was genotyped at CCR5 G2455A, D32, CCR2 V64I,
RANTES G403A, C28G, macrophage inflammatory protein
(MIP)–1a T113C, and stromal cell–derived factor (SDF) 1 3′A
and their HLA loci, as described elsewhere [54].
Calculations and statistics. HIV-1 RNA measurements
were normalized to the input of total cellular RNA (expressed
in copies/106 cell equivalents), assuming that 1 mg of total cel-
lular RNA represents 106 cell equivalents [59]. To represent
specimens that were PCR negative in our analysis, mean de-
tection limits of negative PCR tests were used (RNA plasma,
8 copies/mL; extracellular usRNA, 0.7 copies/106 cells; and
msRNA encoding nef and msRNA encoding tat/rev, 3.6 copies/
106 cells). Copy numbers of intracellular usRNA and msRNA
encoding nef were obtained by subtraction of copy numbers
obtained from independent PCR assays (figure 1B and 1C). In
11% of the specimens positive for any msRNA ( ),np 38
msRNA encoding nef could not be calculated, because the dif-
ference resulted in a nominally negative value, presumably be-
cause of sequence variations on the primer-binding sites used
for the PCR of msRNA. These data were excluded from the
analysis. Similarly, in 1% of the samples positive for usRNA
( ), determinations of intracellular usRNA had to be ex-np 82
cluded. Pearson correlation analyses and 2-tailed t tests not
adjusted for multiple comparisons were performed on log10-
transformed values by use of GraphPad Prism software (version
3.03; AMPL Software). STI-induced changes of HIV-1 RNA
levels were calculated as follows: D 10 (RNA copiesRNAp log
at day copies at day 0).14/RNA
RESULTS
Kinetics of HIV-1 RNA levels after STI. The aim of the pres-
ent study was to characterize HIV-1 replication in PBMCs after
STI and to compare it to viral rebound in plasma. Thus, before
and during 2 weeks of STI, we quantified free HIV-1 particles
in plasma (plasma HIV-1 RNA), intracellular and extracellular
PBMC-associated usRNA species, and msRNA species encoding
tat/rev or nef (figure 1). Longitudinal monitoring of these pa-
rameters was accomplished for 28 HIV-1–infected patients at
baseline (during therapy) and after 2 weeks of STI (figure 2).
To obtain exact kinetics of plasma and cellular viral rebound,
additional samples were obtained from 14 patients on days 4
and 8 of STI (figure 2, gray symbols and lines).
At baseline, extracellular usRNA (figure 2B) and msRNA
encoding tat/rev (figure 2C) were almost completely depleted.
Only 8% and 7% of samples, respectively, were PCR positive.
The other types of viral RNA species analyzed showed pro-
nounced persistence during therapy: plasma HIV-1 RNA was
detected in 46% of samples (at levels !50 copies/mL) (table 1
and figure 2A), intracellular usRNA was detected in all samples
(figure 2D), and msRNA encoding nef was detected in 44% of
samples (figure 2E).
STI resulted in significant viral rebound in plasma as early
as day 4 (figure 2A) and further increases on days 8 and 14 of
STI. On day 14, 86% of the patients had a substantial increase
in plasma viremia, defined here as a more than one-half log10
increase over baseline. In contrast, an equivalent viral rebound
in PBMCs, in 1 or several of the cell-associated viral RNA
species was observed in only 50% of the patients and became
significant only at day 14. The increase in intracellular usRNA
reached borderline statistical significance ( ) and, over-Pp .046
all, was low in magnitude (figure 2D). Changes in extracellular
usRNA (figure 2B) and msRNA encoding tat/rev (figure 2C)
or nef (figure 2E) were more pronounced ( ).P .003
The kinetics of rebound in msRNA encoding tat/rev and in
extracellular usRNA were intriguingly parallel, showing deple-
tion during therapy and significant increase after day 8 of STI
(figure 2B and 2C). This observation was substantiated by the
finding that changes in msRNA encoding tat/rev and changes
in extracellular usRNA between days 0 and 14 were correlated
with high significance ( ; [Pearson test]).2r p 0.72 P ! .0001
This tight linkage of increases of extracellular usRNA with in-
creases of msRNA encoding tat/rev, a class of viral RNA strictly
required for viral production, supports the concept that the
pool of cell-associated extracellular virions is a surrogate for
productive infection, because it includes a substantial fraction
of virions bound to their progenitor cells [16, 18].
Predictors of cellular viral rebound after STI. To identify
predictors of viral rebound, during-therapy plasma levels of
HIV-1 RNA and intracellular usRNA and msRNA encoding
nef, which were detectable at baseline in 140% of patients, were
examined for their association with STI-induced increases in
the 2 parameters representing cellular viral rebound (i.e., ex-
tracellular usRNA and msRNA encoding tat/rev). During-ther-
apy levels of msRNA encoding nef predicted STI-induced
changes of extracellular usRNA with high significance ( 2r p
; [Pearson test]) (figure 3A). The association be-0.45 Pp .003
tween msRNA encoding nef and changes of msRNA encoding
tat/rev was weaker but still significant ( ;2r p 0.31 Pp .046
[Pearson test]) (figure 3B).
Baseline plasma levels of HIV-1 RNA and intracellular
usRNA failed to predict cellular viral rebound after STI (P 1
). No significant correlation was observed when the different.13
baseline levels of HIV-1 RNA were probed for increases in
msRNA encoding nef or in intracellular usRNA ( ).P 1 .1
In a further analysis, we investigated whether HIV-1 RNA
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Figure 2. Kinetics of HIV RNA species levels during structured treatment interruption. Black diamonds and lines denote mean of log10 HIV RNA
copies/mL of plasma (RNA plasma) (A), extracellular unspliced RNA (usRNA-extra) (B), multiply spliced RNA (msRNA) encoding tat/rev (msRNA-tat/
rev) (C), intracellular usRNA (usRNA-intra) (D), and msRNA encoding nef (msRNA-nef) (E). Gray diamonds and lines show single kinetics of 14 patients
who were monitored at study days 0, 4, 8, and 14. P values indicate the results of t tests in comparison to the mean of log10 copy numbers at day
0. Error bars show SDs.
levels at days 4 and 8 of STI could predict cellular viral rebound
at day 14 of STI. Most of the various parameters tested failed
to predict elevations. Only plasma levels of viremia at day 8
predicted increases in extracellular usRNA with high signifi-
cance ( ; [Pearson test]) (figure 3C), as well2r p 0.85 P ! .0001
as changes of msRNA encoding tat/rev ( ;2r p 0.49 Pp .02
[Pearson test]) (figure 3D). Thus, the substantial rebound of
newly produced viral antigens and, likely, infectious viral par-
ticles in plasma around day 8 of STI had a significant effect
on cellular viral rebound in PBMCs 1 week later.
To determine whether host genetic factors showed a marked
influence on cellular viral rebound after STI in the present anal-
ysis, the patients were genotypically tested at the following genetic
loci, which can influence HIV-1 replication: CCR5 G2455A and
D32, CCR2 V64I, RANTES G403A and C28G, MIP-1a T113C,
and SDF1 3′A. In addition, HLA genotypes were determined.
None of the tested genetic polymorphisms showed significant
linkage with the magnitude of rebound in extracellular usRNA
or msRNA encoding tat/rev (data not shown).
DISCUSSION
The present analysis of the kinetics and the magnitude of viral
rebound in plasma and PBMCs from patients after short-term
STI resulted in 2 major findings. First, the expression of msRNA
encoding tat/rev and PBMC-associated viral particles were
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Figure 3. Predictors of structured treatment interruption (STI)–induced changes in cellular HIV-1 RNA levels. Paired correlation of expression levels
of msRNA (msRNA) encoding nef (msRNA-nef) during therapy (A and B) or levels of HIV RNA in plasma (RNA plasma) on day 8 (C and D), compared
with STI-induced changes in extracellular unspliced HIV RNA (usRNA-extra) (A and C) and multiply spliced RNA (msRNA) encoding tat/rev (msRNA-
tat/rev) (B and D). Black diamonds, polymerase chain reaction (PCR)–positive measurements of baseline msRNA-nef or day-8 RNA plasma; white
diamonds, average detection limits of undetectable measurements on the X-axis. Note that 2 measurements positive for msRNA-nef were below the
average detection limit of the PCR used. Closed and broken lines show the calculated linear regression lines and their 95% confidence intervals.
Correlation coefficients and P values calculated from pairs with PCR-positive values on the X-axis are indicated within each panel. Analyses including
PCR-negative measurements (represented by detection limits) also resulted in statistically significant correlations (A: , , ; B:2r p 0.32 Pp .003 np 26
, , ; C: , , ; D: , , ).2 2 2r p 0.16 Pp .04 np 27 r p 0.90 P ! .0001 np 14 r p 0.51 Pp .004 np 14
shown to be tightly linked and arose from virtually undetectable
baseline levels with almost identical kinetics after STI. Since
expression of msRNA encoding tat/rev is a prerequisite of viral
replication and production of virions is its consequence, the
concomitant rebound of these 2 parameters is a specific cor-
relate of newly reappearing productive infection in PBMCs after
STI. Second, during-therapy levels of msRNA encoding nef and
viral rebound in plasma after 8 days of STI predicted the mag-
nitude of the cellular viral rebound. Thus, the pools both of
nonproductively HIV-1–infected cells persisting during therapy
and of virions newly produced after STI determined cellular
viral rebound in PBMCs.
Short-term STI led to substantial rebound of viral replication
both in plasma and PBMCs, as indicated by significant increases
in HIV-1 RNA species in both compartments. Of note, the
earlier and more frequent rebound in plasma viremia, com-
pared with cellular viral rebound in PBMCs, reconfirms that
plasma HIV-1 RNA reflects the viral progeny from not only
PBMCs but also from the much larger pool of infected cells in
different lymphatic tissues [18, 60] and, potentially, in other
viral reservoirs, such as the central nervous system and the
genital tract [61–63].
One key parameter that appeared as a specific correlate of
cellular viral rebound was an increased amount of cell-associated
extracellular usRNA, which was tightly correlated ( 2r p 0.72
[Pearson test]) to expression of msRNA encoding tat/rev, which
has also been perceived as an indicator of productively infected
cells [16, 18, 34, 36]. It may be argued that these cell-associated
virions reflected HIV-1 particles captured primarily from the
plasma. However, on days 4 and 8 of STI, when plasma levels
of HIV-1 RNA were already significantly elevated, almost no
PBMC samples positive for extracellular usRNA were discernible
(figure 2). Furthermore, the kinetics of extracellular usRNA levels
mirrored changes in cell-associated HIV-1 RNA species better
than the kinetics of HIV-1 RNA in plasma did. Hence, our find-
ings support the concept that extracellular usRNA denotes pro-
ductive HIV-1 infection at the cellular level [16, 18].
In contrast to extracellular usRNA and msRNA encoding
tat/rev, intracellular usRNA and msRNA encoding nef showed
complete or partial persistence during therapy. Like residual
intracellular usRNA, which has been shown to stem, to a great
extent, from latently infected cells in patients receiving effective
antiretroviral therapy [16, 18, 23], msRNA encoding nef may
also be synthesized in HIV-1–infected cells lacking virion pro-
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duction. HIV-1 RNA species encoding nef [32] and usRNA [16,
18, 32, 64] have been shown to be the predominant cellular
HIV-1 RNA species in patients receiving effective antiretroviral
therapy, whereas HIV-1 RNA species encoding tat/rev were
found to be 10–100 times less abundant [16, 18, 32] and fre-
quently depleted [16, 18, 34, 64]. Therefore, tat-independent
transcription [65–68] may likely be the source of persisting
cell-associated HIV-1 RNA species in patients receiving potent
antiretroviral therapy [16, 18]. To further define the role of
these residual cellular HIV-1 transcripts in the transition from
repressed to active viral replication, the capacity of their baseline
levels to predict rebound of productively HIV-1–infected
PBMCs after 14 days of STI was probed. Of interest, during-
therapy levels of msRNA encoding nef significantly predicted
the STI-induced rebound of both msRNA encoding tat/rev and
extracellular usRNA.
In addition, rebound of productive infection in PBMCs was
significantly associated with the elevated levels of plasma vi-
remia on day 8 of STI. This finding implies that either cellular
viral rebound was initiated by new infections via virions from
the plasma or newly arising viremia might have acted as a trig-
ger for activation of latently infected T cells [16, 23, 69–72] to
a productive phenotype. These 2 hypotheses are not mutually
exclusive, and it cannot be discerned conclusively which ex-
planation applies here. Of note, the finding that baseline ex-
pression of msRNA encoding nef also predicts the reappearance
of productively infected cells is compatible with both views:
either the expression of nef derived from HIV-infected mac-
rophages in PBMCs paved the way for cellular rebound by
facilitating new productive infection of bystanding resting T
cells [43] with newly produced virions from the plasma or the
expression of msRNA encoding nef occurred in latently infected
cells primed for activation of the integrated provirus to a pro-
ductive phenotype [44, 47]. Thus, subsequent activation of
these latently infected cells by antigenic or cytokine stimuli
induced by the high levels of viremia, which preceded and
predicted cellular rebound, might have been facilitated.
In summary, we have demonstrated that msRNA encoding
tat/rev and extracellular usRNA can serve as cellular markers
of productive infection. Furthermore, the present data suggest
that during-therapy expression of msRNA encoding nef likely
facilitates cellular viral rebound by priming latently infected
cells to move into a productive state or by activating resting
target cells for productive infection.
Quantification of the cellular correlates of latent, preacti-
vated, and ongoing HIV-1 replication, as performed in the
present study, will be helpful in gaining further insights into
the mechanisms and the cell types that govern transition from
latent to productive HIV-1 infection in vivo. These measure-
ments might also become important in monitoring future at-
tempts to “purge” latent HIV-1 reservoirs, to move toward
eradication of the infection or its control in the absence of
antiretroviral combination therapy [20, 21].
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per, M. Opravil, F. Paccaud, G. Pantaleo, L. Perrin, J.-C. Pif-
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